Role of the endocannabinoid system in Alzheimer's disease: new perspectives.

The role of the endocannabinoid system in several diseases is currently under intense study. Among these, Alzheimer's disease may be a new promising area of research. We have recently reported the existence of profound changes in the location and density of several elements of this system in Alzheimer's disease tissue samples, indicating that a non-neuronal endocannabinoid system is up-regulated in activated glia. Additional data from other groups suggest that glial cells may be important elements in the regulation of endocannabinoid system activity, both in health as in disease. Some of these aspects are briefly discussed in the present review.

[1]  S. Gauthier,et al.  Say NO to Alzheimer’s disease: the putative links between nitric oxide and dementia of the Alzheimer’s type , 2001, Brain Research Reviews.

[2]  S. Ben-Shabat,et al.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury , 2001, Nature.

[3]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[4]  J. Borrell,et al.  Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis , 2003, The Journal of Neuroscience.

[5]  F. Berrendero,et al.  Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35s]guanylyl-5′-O-(thio)-triphosphate binding in the basal ganglia of aged rats , 1998, Neuroscience.

[6]  C. Newton,et al.  Cannabinoids and the immune system. , 2001, Pain research & management.

[7]  P. Mcgeer,et al.  Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid‐type CB2 receptor , 2003, British journal of pharmacology.

[8]  D. Piomelli,et al.  Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. , 2001, The Journal of pharmacology and experimental therapeutics.

[9]  M. Herkenham,et al.  Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. , 1994, The Journal of pharmacology and experimental therapeutics.

[10]  L. Barbeito,et al.  The molecular bases of Alzheimer's disease and other neurodegenerative disorders. , 2001, Archives of medical research.

[11]  R. Mechoulam,et al.  Cannabinoids and brain injury: therapeutic implications. , 2002, Trends in Molecular Medicine.

[12]  V. Nguyen,et al.  Immunological aspects of microglia: relevance to Alzheimer's disease , 2001, Neurochemistry International.

[13]  N. Stella,et al.  Cannabinoids and neuroinflammation , 2004, British journal of pharmacology.

[14]  G. Cabral,et al.  The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. , 1999, The Journal of pharmacology and experimental therapeutics.

[15]  B. Cravatt,et al.  Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. , 2002, The Journal of pharmacology and experimental therapeutics.

[16]  V. Pickel,et al.  Ultrastructural Localization of the CB1 Cannabinoid Receptor in μ-Opioid Receptor Patches of the Rat Caudate Putamen Nucleus , 2001, The Journal of Neuroscience.

[17]  C. Felder,et al.  The endocannabinoid nervous system: unique opportunities for therapeutic intervention. , 2001, Pharmacology & therapeutics.

[18]  D. Deutsch,et al.  Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry , 1998, Neuroscience Letters.

[19]  K. Mackie,et al.  Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.

[20]  K. Waku,et al.  Evidence That 2-Arachidonoylglycerol but Not N-Palmitoylethanolamine or Anandamide Is the Physiological Ligand for the Cannabinoid CB2 Receptor , 2000, The Journal of Biological Chemistry.

[21]  N. Milton.  Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide , 2002, Neuroscience Letters.

[22]  M. Calero,et al.  Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. , 2002, Brain research. Molecular brain research.

[23]  L. Volicer,et al.  Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease , 1997, International journal of geriatric psychiatry.

[24]  K. Mackie,et al.  Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.

[25]  Xavier Alvarez,et al.  Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system , 2001, Glia.

[26]  D. Deutsch,et al.  Evidence against the presence of an anandamide transporter , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Alberto Rábano,et al.  Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.

[28]  A. Izzo,et al.  Neuroprotective effect of cannabidiol, a non‐psychoactive component from Cannabis sativa, on β‐amyloid‐induced toxicity in PC12 cells , 2004, Journal of neurochemistry.

[29]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[30]  M. Herkenham,et al.  Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains , 1994, Neuroscience.

[31]  D. Giulian.  Microglia and the immune pathology of Alzheimer disease. , 1999, American journal of human genetics.

[32]  F. Drago,et al.  Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. , 2003, European journal of pharmacology.

[33]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[34]  F. Bymaster,et al.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. , 2002, The Journal of pharmacology and experimental therapeutics.

[35]  T. Freund,et al.  A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. , 2002, Chemistry and physics of lipids.

[36]  The fatty acid amide hydrolase (FAAH). , 2002, Chemistry and physics of lipids.

[37]  J. Ramos,et al.  UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. , 2002, European journal of pharmacology.

[38]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.